1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
SD BioSensor, Inc

SD BioSensor, Inc

137310.KS
SD BioSensor, IncKR flagKorea Exchange
6,320.00
KRW
-110.00
- -
755.99BMarket Cap
SD BioSensor, Inc
137310.KS
(Korea Exchange)

Recent

price

6,320.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
879.29
18,068.5
30,043.34
28,944.82
5,914.54
5,681.61
5,937.39
6,002.98
Revenue per Share
38
6,597
11,161
8,997
-4,219
-805
-4,279
-3,931.32
Basic EPS, GAAP
-110
4,717.42
11,644.78
5,810.25
-3,491.02
618.61
2,506.93
2,631.89
Free Cash Flow per Basic Share
- -
- -
510.96
1,961.92
266.55
0.31
202.07
201.81
Dividend per Share
176.51
7,198.22
17,640.07
24,038.51
17,569.07
15,126.61
12,392.93
11,985.21
Book Value per Share
1,594.88
8,058.6
22,498.61
28,425.65
8,039.38
6,853.78
9,020.08
8,919.09
Tangible Book Value per Share
83
93
98
101
111
122
120
120
Basic Weighted Avg Shares
72,962
1,686,163
2,929,961
2,932,001
655,677
694,574
710,581
718,784
Sales/Revenue/Turnover
2.08
43.78
47.36
39.11
-37.84
-7.78
-11.39
-10.84
Operating Margin (%)
4,331
7,974
19,115
40,820
137,541
141,694
134,266
130,464
Depreciation Expense
3,153
615,636
1,088,471
911,362
-467,712
-98,411
-512,106
-470,727
Net Income, GAAP
- -
13.33
25.7
26.83
- -
- -
- -
- -
Effective Tax Rate (%)
4.32
36.51
37.15
31.08
-71.33
-14.17
-72.07
-65.49
Profit Margin (%)
78,668
599,859
1,826,919
2,220,286
644,212
761,830
766,563
770,948
Working Capital
2,785
14,536
18,378
11,729
467,533
599,424
357,369
302,037
LT Debt
137,914
757,551
2,232,209
2,946,781
2,831,546
2,932,281
2,336,866
2,373,941
Total Equity
- -
123.58
59.11
29.18
- -
- -
- -
- -
Return on Invested Capital (%)
- -
165.88
88.55
43.34
- -
- -
- -
- -
Return on Capital (%)
- -
179.38
91.01
43.86
-21.34
-5.18
-30.74
-27.37
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
10,286
311,659
7,578
LT Borrowings
605,008
346,845
291,810
LT Finance Leases
11,113
10,524
10,227
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
1,189,287
1,065,927
915,994

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,226,798
1,232,814
960,277
Cash, Cash Equivalents & STI
778,101
774,175
497,602
Accounts Receivable, Net
122,809
138,069
141,197
Inventories
248,598
222,115
239,453
Total Current Liabilities
163,636
466,251
189,330
Payables & Accruals
- -
- -
- -
ST Debt
10,286
311,659
7,578
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41.2%
-20.31%
Free Cash Flow
- -
24.25%
296.73%
Net Income, GAAP
- -
50.13%
420.38%
Sales/Revenue/Turnover
- -
0.88%
2.3%
Total Cash Common Dividend
- -
- -
63,430.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
176,389
167,461
170,606
180,118
694,574
2025
185,326
166,501
164,188
194,566
710,581
2026
193,529
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-91
-153
532
- -
-805
2025
-156
2,301
-81
- -
-4,279
2026
189.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.31
2025
0.16
201.62
-0.01
- -
202.07
2026
- -
- -
- -
- -
- -
Similar Companies
Advanced Medical Solutions Group plc (AMS.L)
Akoya Biosciences, Inc. (AKYA)
Baxter International Inc. (BAX.SW)
Signature Eyewear, Inc. (SEYE)
Straumann Holding AG (STMN.SW)
Fielmann AG (FLMNF)
Business
SD BioSensor, Inc. (137310.KS) is a South Korea-based in vitro diagnostics company that develops, manufactures and markets point-of-care diagnostic solutions for infectious diseases, chronic conditions and general health screening; its core product platforms include STANDARD Q rapid diagnostic tests for parameters such as COVID-19, influenza and other infectious agents; STANDARD F fluorescent immunoassay systems for multi-parametric laboratory testing; STANDARD E enzyme-linked immunosorbent assays for mass screening; STANDARD M and M10 point-of-care molecular diagnostic systems with qPCR reagents and nucleic acid extraction kits for near-patient clinical decisions; STANDARD i chemiluminescent immunoassay analyzers; procell Dx interferon gamma release assays for tuberculosis and immune status evaluation; and blood glucose monitoring systems including meters like SD GlucoNavii with NFC connectivity for self-testing. Founded in 2010 and headquartered in Suwon, Gyeonggi-do, South Korea, the company operates globally with production facilities including a new plant in Gurugram, India that boosts annual capacity by over 2.9 times, serving markets in Asia, Europe, the Americas and low- and middle-income countries through distributors and subsidiaries. In recent developments, SD BioSensor completed its 2023 acquisition of a 60% stake in Meridian Bioscience, Inc. for $1.53 billion in partnership with SJL Partners to expand U.S. diagnostics capabilities; signed a December 2024 tripartite MOU with Japan's RIT/JATA and Korea's ITRC for R&D of M10 platform-based tests targeting extensively drug-resistant tuberculosis; secured WHO and Medicines Patent Pool sublicensing for rapid diagnostic technology transfer to Codix Bio in Nigeria in May 2025; launched 28 new products including STANDARD M10 in 2024 with KRW 87.9 billion R&D investment; obtained European CE-IVDR certifications for five blood glucose meters and molecular diagnostics in 2025; and participated in events like the 2025 Fall Conference of Korean Clinical Hypertension Society while planning a continuous glucose monitoring system rollout.